Felzartamab And Izastobart/HIB210 — Contingent consideration obligations

Biogen Felzartamab And Izastobart/HIB210 — Contingent consideration obligations decreased by 94.5% to $35.00M in Q2 2025 compared to the prior quarter.

Analysis

StatementSegment

CategoryLeverage

SignalContext dependent

VolatilityVolatile

First reportedQ2 2024

Last reportedQ2 2025

Rolls up toContingent Consideration Liability (Non-Current)

How to read this metric

An increase in this liability often reflects improved expectations for the commercial or clinical success of the assets, whereas a decrease may signal lower projected performance or the settlement of obligations.

Detailed definition

This metric quantifies the fair value of liabilities recognized on the balance sheet related to contingent consideration...

Peer comparison

Standard accounting practice for 'contingent consideration' or 'earn-out liabilities' following M&A activity in the life sciences sector.

Metric ID: biib_segment_felzartamab_and_izastobart_hib210_contingent_consideration_obligations

Historical Data

2 periods

	Q2 '24	Q2 '25
Value	$640.00M	$35.00M
QoQ Change	—	-94.5%
YoY Change	—	-94.5%

Range$35.00M – $640.00M

Avg YoY Growth-94.5%

Median YoY Growth-94.5%

Similar Metrics at Other Companies

ResMedRMD View metric

Natera, Inc.NTRA View metric

LPL Financial HoldingsLPLA View metric

Brown & BrownBRO View metric

InsmedINSM View metric

Vertex PharmaceuticalsVRTX View metric

Frequently Asked Questions

What is Biogen's felzartamab and izastobart/hib210 — contingent consideration obligations?: Biogen (BIIB) reported felzartamab and izastobart/hib210 — contingent consideration obligations of $35.00M in Q2 2025.
What does felzartamab and izastobart/hib210 — contingent consideration obligations mean?: The current estimated liability for future payments owed to sellers of acquired assets, adjusted for the likelihood of meeting performance targets.